Figure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma.

Figure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma.

The plot shows the best percent change in tumor volume in the 21 evaluable patients (eligible patient population) that were measurable by CT scan or by mSWAT for patients with cutaneous involvement.

Format

JPEG

Source

Corvus Pharmaceuticals, Inc.

Downloads